Wudang boosts development of healthcare industry

In Guiyang, the capital of Southwest China's Guizhou province, Wudang district will promote the upgrading of its industrial chain, boost major industrial breakthroughs and push forward the healthcare industry's high-quality development in 2021, according to local media reports.

Many enterprises in the district are now working to promote innovation, stabilize the market and seek growth in the first quarter.

Workers are busy at a workshop of Guiyang Xintian Pharmaceutical Co Ltd in Wudang district. [Photo/Guiyang Daily]

Guiyang Xintian Pharmaceutical Co Ltd has already resumed production in the district on Feb 19, with automated production lines running at full capacity and workers packing medicine boxes.

A capacity improvement upgrade on a production line for traditional Chinese medicine (TCM) recently entered the trial operation stage and is expected to produce 1.1 billion additional capsules after formal operations begin.

According to company officials, the project adopts big data intelligent warehouse technology and modern logistics technology.

Taking innovation as the driving force of its development, Guiyang Xintian Pharmaceutical has grown from a small workshop into a leading TCM manufacturing enterprise in the province.

The company has attached great importance to research and development since its establishment. It regards R&D capabilities as a significant part of its core competitiveness and one of the most critical factors for achieving sustainable development.

With average annual R&D funds of more than 20 million yuan ($3.10 million), the company currently has 36 invention patents and six design patents, according to a company official.

The Zhihui Yunjin incubation base in Guiyang's Wudang district. [Photo/Guiyang Daily]

Guizhou Lizhijian Biotechnology Co Ltd, a company based at Zhihui Yunjin incubation base, started production on Feb 8.

The company now produces 13 independently developed products, with a daily output value of up to 200,000 yuan, according to the company's chairman Zhang Yuanbo.

Zhang said that since its establishment, the company has been working on automation, intelligence and humanization, and it has invested a considerable amount of funding and human resources in R&D.

Last year, the company took roughly a month to develop a new coronavirus nucleic acid detection kit and a new coronavirus antibody. Its innovations filled the gap in the R&D and production of new coronavirus diagnostic reagents in Guizhou province, Zhang added.

The company currently has two fully intelligent production lines, achieving an output value of 13 million yuan in 2020.

Talking about the future, the chairman said that the company would continue to increase investment in innovation and R&D and strive to build a complete industrial chain integrating intelligent manufacturing, precision medicine and big data.